Jay Goodman, professor of pharmacology and toxicology and IIT-affiliated faculty member, was recently awarded the distinction of Fellow by the American Association for the Advancement of Science (AAAS) along with five other distinguished MSU faculty members. These individuals were selected for this honor because of their efforts toward advancing science applications that are deemed scientifically or socially distinguished. AAAS Fellow's lifetime honor comes with an expectation that recipients maintain the highest standards of professional ethics and scientific integrity.
A Michigan State University study led by a physiology graduate student in the College of Human Medicine has found that new drug combinations may prevent melanoma, an often deadly form of skin cancer, from becoming resistant to treatment.
The study published in Oncogene, one of the world’s leading cancer journals, “could be very important for a subset of melanoma patients,” said Richard Neubig, chair of the Department of Pharmacology and Toxicology in the Colleges of Osteopathic Medicine and Human Medicine. He estimated that the findings could help about half of the melanoma patients whose cancer becomes drug resistant.
Health Innovation Partners and Michigan State University broke ground on the next phase of the university’s Grand Rapids Innovation Park, the Doug Meijer Medical Innovation Building.
The 205,000-square-foot building has received strong national interest since the initial project announcement in 2018. The university and developers have been working with potential tenants eager to help bring the unique concept to life. Current confirmed tenants include the MSU College of Human Medicine, BAMF Health and Spectrum Health. The building is anticipated to open in late 2021.
The married couple’s step-by-step approach has revealed — for the first time — a new way to detect and attack cancer cells using technology traditionally reserved for solar power. The results, published in the current issue of Scientific Reports, showcase dramatic improvements in light-activated fluorescent dyes for disease diagnosis, image-guided surgery and site-specific tumor treatment.
“We’ve tested this concept in breast, lung cancer and skin cancer cell lines and mouse models, and so far, it’s all looking remarkably promising,” says Sophia Lunt, PhD, MSU biochemistry and molecular biologist.